“Recognising gender difference is essential for Parkinson’s research”
Women and Parkinson's
Author: Marina PicilloPublished: 5 December 2019
Prep: Cook: Serves:
In the sixth in our Women and Parkinson’s series, Italian neurologist Marina Picillo shares her findings from studies focussing on gender differences in Parkinson’s, highlights the role cultural bias plays in the results – and reflects on how research into such differences is a relatively “new phenomenon”
I started working in Parkinson’s research when I was in medical school, and developed an interest in gender differences within the condition about six years ago. I began looking into how non-motor symptoms affect men and women differently – with one study revealing that despite women experiencing higher rates of anxiety, depression and panic attacks than men, they remain largely untreated. Men and women experience very different problems. Recognising that is essential for Parkinson’s research purposes – and to ensure better treatment for patients.
The acknowledgment of gender differences in the medical field is quite a new phenomenon – it only started about 30 years ago. It took a while until it filtered down into Parkinson’s research, and I think we are still a little bit behind compared to other research fields. This is probably because two thirds of people with Parkinson’s are men and so the data is dramatically driven by men. But the mentality is changing. The design of studies and the treatment of patients is slowly being given more thought as researchers, the media and the patients themselves call for change.
Diagnostic delays and dyskinesia
Throughout my research I have come across a number of issues that are specific to women. Women are more prone to developing dyskinesia – uncontrollable, involuntary movements that can be a side-effect of levodopa. Some data suggests this is because women have a lower body weight than men, and clinicians prescribe the same dose regardless. Our follow up studies aim to find out more about the metabolism rate of levodopa as we believe that will be different according to gender. If that’s the case, it could seriously impact the way clinicians prescribe the drug in the future.
There’s also the ‘diagnostic delay’ to consider. According to research, on average women are diagnosed a few years later than men. There are a few explanations for this. Parkinson’s is not only less frequent in women, but also appears later in women than men. This is because oestrogen, the primary female sex hormone, is thought to play a ‘protective role’ in the development of Parkinson’s.
Women also generally visit specialists later than men. This may be because they pay less attention to themselves and their health as caregivers. Generally they’re likely to be less involved with their own care – which is an important psychosocial aspect to think about.
I was recently involved in a study which showed that an active sex life improves motor and non-motor symptoms – and quality of life – in people with Parkinson’s, although the results actually only applied to men. This is due to two things. One, women were simply less represented in the study than men. And generally women are less willing to talk about sexual issues than men due to cultural bias.
Women as caregivers
The next topic I’d like to focus my research on is why women are less likely to undergo complex treatments like deep brain stimulation (DBS). It’s a paradox, since women experience worse motor and non-motor fluctuations and more disabling dyskinesia. I think cultural reasons are once more at play here. Generally, worldwide, women have a central role in caring for their families. When a woman is sick, or has to take time off, this impacts on the whole family and causes difficulties. I would like to find out more about why women feel like this, and why there is such a gap in the uptake of these beneficial treatments.
More widely, I would like to see more research into women with young onset Parkinson’s – particularly for those who might still be thinking about having children. There is very little research available on this subject currently.
Though there aren’t symptoms that are unique to women, there are certainly issues that are unique to women with Parkinson’s. There has been progress, and everything is changing – but we still have some way to go.
Need to know: Marina Picillo is a researcher at the Centre for Neurodegenerative Diseases at the University of Salerno, Italy and has authored over 40 research papers. She completed a clinical and research fellowship at the University of Toronto, Canada, where she worked with advanced treatments for Parkinson’s such as DBS.
Parkinson’s and research: the facts
Motor fluctuations, including levodopa-induced dyskinesia, are more common in women with Parkinson’s
Women with Parkinson’s experience a more rapid disease progression than men – and a lower survival rate
Women with Parkinson’s report higher rates of depression and anxiety than men
Women and Parkinson’s: Our campaign
It is estimated that three million women worldwide are living with Parkinson’s – yet their specific needs and experiences are often ignored, leading to disparities in diagnosis, treatment and medication. Each week, we’ll be sharing the little-heard stories of women with the condition to find out how their lives are being affected by a shocking data gap when it comes to women and Parkinson’s. This is just the start.
We want to raise awareness of women’s experience of the condition within the medical profession, so that women’s symptoms are taken seriously.
We think more research is needed into the impact of Parkinson’s on women, so that they can benefit from tailored medication and treatment.
We want to explore ways to offer better support for those women managing the condition alongside caring responsibilities.
Join us – #WomenAndParkinsons.
For more information on women and Parkinson’s please visit Parkinson’s Europe website.
If you have a story to tell about being a woman with Parkinson’s – or some information about the impact of the condition on women for us to share with the global Parkinson’s community – please get in touch.
Introducing the “first-ever” legislation devoted solely to ending Parkinson’s disease
Learn about the US National Plan to End Parkinson’s Act
2 days ago
Chemical used in dry cleaning may be associated with Parkinson’s disease
The chemical trichloroethylene (TCE) has been used across a number of industries: to decaffeinate coffee, degrease metal parts, remove stains and dry-clean clothing. It’s currently banned in the European Union and the US states New York and Minnesota, except for authorised industrial uses. Now, scientists led by Dr Ray Dorsey in the US have conducted new research claiming that TCE could be linked to an increased risk of Parkinson’s. Published in the ‘Journal of Parkinson’s Disease’, the study investigated case studies of seven people who were exposed to TCE prior to a Parkinson’s diagnosis – including basketball legend Brian Grant. The researchers “postulate that this ubiquitous chemical is contributing to the global rise of Parkinson’s and that TCE is one of its invisible and highly preventable causes”. They called for the cleaning of TCE-contaminated sites and for indoor air exposure to be diminished – as well as for further studies to be…
Could certain cancers be linked to Parkinson’s disease?
Previous research has suggested that people with Parkinson’s may generally be less likely to develop most cancers. However, a new international study has found a potential genetic link between certain types of cancer and the condition. The team analysed genetic data from genome-wide association studies – a research approach that aims to identify gene variations associated with disease risk – to recognise common genetic risk factors between cancer and Parkinson’s. The findings uncovered a genetic link between the condition and both prostate cancer and melanoma. Meanwhile, the sum of various gene variants (otherwise known as the polygenic risk score) that contribute to Parkinson’s was significantly associated with a higher risk of breast cancer. “Our results suggest the importance of shared genetic variants between Parkinson’s and some cancers,” the researchers concluded in the study, which was published in the medical journal ‘Movement Disorders’. They highlighted the need for further studies to…
Investigational Parkinson’s disease dementia therapy fails in clinical trial
Research into new potential therapies for people with Parkinson’s is complex, which means that not all clinical trials will successfully move on to the next phase. This proved to be the case for US biotech company Aptinyx, which announced that it will halt further development work on an investigational therapy following “disappointing” results in the second phase of its study. The research had set out to examine the effect of NYX-458 – an oral therapy created to modulate the activity of receptors in the brain that are responsible for communication between neurons. The aim of the therapy was to improve cognition in people with cognitive impairment linked to Parkinson’s or Lewy body dementia. Yet, when compared to a placebo, the therapy didn’t demonstrate “meaningful improvements” in cognitive function. Dr Andy Kidd, president and CEO at Aptinyx, said: “We are very disappointed that the results of this Phase 2 study did…